0001415889-24-002388.txt : 20240202 0001415889-24-002388.hdr.sgml : 20240202 20240202181605 ACCESSION NUMBER: 0001415889-24-002388 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Andriole Michael T. CENTRAL INDEX KEY: 0001698751 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35867 FILM NUMBER: 24593230 MAIL ADDRESS: STREET 1: C/O ENDOCYTE, INC. STREET 2: 3000 KENT AVENUE, SUITE A1-100 CITY: WEST LAFAYETTE STATE: IN ZIP: 47906 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHIMERIX INC CENTRAL INDEX KEY: 0001117480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330903395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919.806.1074 MAIL ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 4 1 form4-02022024_110200.xml X0508 4 2024-02-01 0001117480 CHIMERIX INC CMRX 0001698751 Andriole Michael T. 2505 MERIDIAN PARKWAY, SUITE 100 DURHAM NC 27713 true true false false PRESIDENT AND CEO 0 Common Stock 2024-02-01 4 A 0 83750 0 A 448765 D Stock Option (Right to Buy) .93 2024-02-01 4 A 0 502500 0 A 2034-01-31 Common Stock 502500 502500 D The shares being reported are being issued pursuant to restricted unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 20,937 shares subject to the RSUs will vest on the one-year anniversary of the date of grant, 20,937 shares subject to the RSUs will vest on the second-year anniversary of the date of grant, 20,937 shares subject to the RSUs will vest on the third-year anniversary of the date of grant, and 20,939 shares subject to the RSUs will vest on the fourth-year anniversary of the date of grant. 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. /s/ Michael Alrutz, Attorney-in-Fact 2024-02-02